{"drugs":["Ataluren"],"mono":{"0":{"id":"931055-s-0","title":"Generic Names","mono":"Ataluren"},"1":{"id":"931055-s-1","title":"Dosing and Indications","sub":{"0":{"id":"931055-s-1-4","title":"Adult Dosing","mono":"<ul><li>Ataluren has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Duchenne muscular dystrophy, Associated with nonsense mutation of dystrophin gene:<\/b> administer ORALLY in 3 divided doses each day: 10 mg\/kg in the morning, 10 mg\/kg 6 hours later, and 20 mg\/kg in the evening 12 hours after the morning dose for a total dose of 40 mg\/kg\/day (European Medicines Agency-approved dosing)<\/li><\/ul>"},"1":{"id":"931055-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Ataluren has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU) in pediatric patients 5 years or older<\/li><li>safety and efficacy in patients 6 months to 5 years not established<\/li><li><b>Duchenne muscular dystrophy, Associated with nonsense mutation of dystrophin gene:<\/b> 5 years or older, administer ORALLY in 3 divided doses each day: 10 mg\/kg in the morning, 10 mg\/kg 6 hours later, and 20 mg\/kg in the evening 12 hours after the morning dose for a total dose of 40 mg\/kg\/day (European Medicines Agency-approved dosing)<\/li><\/ul>"},"3":{"id":"931055-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Duchenne muscular dystrophy, Associated with nonsense mutation of dystrophin gene<br\/>"}}},"3":{"id":"931055-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931055-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to ataluren or any of its ingredients<\/li><li>concomitant use of IV aminoglycosides<\/li><\/ul>"},{"id":"931055-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- hypertension with coadministration of systemic corticosteroids has been reported; monitoring recommended<\/li><li>Endocrine and Metabolic:<\/li><li>-- increased triglycerides and cholesterol have been reported; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- close monitoring recommended for patients with hepatic impairment<\/li><li>Musculoskeletal:<\/li><li>-- lack of nonsense mutation in the dystrophin gene; use not recommended<\/li><li>Renal:<\/li><li>-- close monitoring recommended for patients with renal impairment<\/li><li>-- small increases in serum creatinine, blood urea nitrogen, and cystatin C have been reported; monitoring recommended<\/li><li>Concomitant use:<\/li><li>--avoid use with other nephrotoxic drugs; if treatment is necessary (eg, vancomycin to treat MRSA), renal monitoring is recommended<\/li><\/ul>"},{"id":"931055-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"931055-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931055-s-4","title":"Drug Interactions","sub":[{"id":"931055-s-4-13","title":"Contraindicated","mono":"<ul><li>Amikacin (probable)<\/li><li>Gentamicin (probable)<\/li><li>Kanamycin (probable)<\/li><li>Netilmicin (probable)<\/li><li>Streptomycin (probable)<\/li><\/ul>"},{"id":"931055-s-4-14","title":"Major","mono":"<ul><li>Dasabuvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><\/ul>"}]},"5":{"id":"931055-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Decrease in appetite (1% to less than 10%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (greater than or equal to 10%), Vomiting (greater than or equal to 10%)<\/li><li><b>Neurologic:<\/b>Headache (greater than or equal to 10%)<\/li><\/ul>"},"6":{"id":"931055-s-6","title":"Drug Name Info","sub":{"3":{"id":"931055-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"931055-s-7","title":"Mechanism Of Action","mono":"Nonsense mutations in the dystrophin gene create premature stop codons that prevent full protein translation resulting in the disease Duchenne muscular dystrophy. Ataluren allows a full ribosomal readthrough of the mRNA such that a full-length protein is encoded. However, the activity is based on continuous exposure to ataluren.<br\/>"},"8":{"id":"931055-s-8","title":"Pharmacokinetics","sub":[{"id":"931055-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 1.5 hours<\/li><li>Bioavailability, Oral: 55% or greater after initial dose; declines by 40% at steady state<\/li><\/ul>"},{"id":"931055-s-8-24","title":"Distribution","mono":"Protein binding: 99.6% <br\/>"},{"id":"931055-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: primarily via uridine diphosphate glucuronosyltransferase (UGT1A9)<\/li><li>Intestine: primarily via uridine diphosphate glucuronosyltransferase (UGT1A9)<\/li><\/ul>"},{"id":"931055-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: Approximately 50%<\/li><li>Renal: Approximately 50%; less than 1% unchanged<\/li><\/ul>"},{"id":"931055-s-8-27","title":"Elimination Half Life","mono":"2 to 6 hours <br\/>"}]},"9":{"id":"931055-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>mix full contents of sachet into at least 30 mL of liquid or 3 tablespoons of semisolid food (eg, yogurt or applesauce) and mix well<\/li><li>amount of liquid or semisolid food may be increased<\/li><li>administer immediately once mixed with liquid or semisolid food and give the entire dose<\/li><li>dispose of unused portion according to local regulations<\/li><li>missed dose, if less than 3 hours after morning or midday dose or less than 6 hours after evening dose: administer missed dose with no changes; if more than 3 hours after morning or midday dose or more than 6 hours after evening dose: skip missed dose and administer next scheduled dose<\/li><\/ul>"},"10":{"id":"931055-s-10","title":"Monitoring","mono":"<ul><li>improvements in muscle function and ambulation may indicate efficacy.<\/li><li>hepatic or renal function; during use in patients with hepatic or renal impairment<\/li><li>lipid panel; annually or as clinically indicated<\/li><li>serum creatinine, BUN, and cystatin C levels; every 6 to 12 months or as clinically indicated<\/li><li>blood pressure; every 6 months or as clinically indicated in patients on concurrent steroid therapy<\/li><\/ul>"},"13":{"id":"931055-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized as drug may cause dizziness.<\/li><li>Side effects may include headache, nausea, vomiting, decreased appetite, constipation, diarrhea, abdominal pain, epistaxis, erythema, enuresis, pyrexia, or fatigue.<\/li><li>Tell patient to maintain adequate hydration.<\/li><li>Instruct patient to take a missed dose as soon as possible if the delay is less than 3 hours after the scheduled morning or midday dose or less than 6 hours after the evening dose. If the delay is more than 3 hours after the morning or midday dose or more than 6 hours after the evening dose, skip the missed dose.<\/li><\/ul>"}}}